Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Health Catalyst (HCAT) EBIT (2018 - 2025)

Health Catalyst (HCAT) has disclosed EBIT for 8 consecutive years, with -$17.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 27.92% year-over-year to -$17.5 million, compared with a TTM value of -$92.3 million through Sep 2025, down 8.44%, and an annual FY2024 reading of -$69.8 million, up 44.99% over the prior year.
  • EBIT was -$17.5 million for Q3 2025 at Health Catalyst, up from -$37.1 million in the prior quarter.
  • Across five years, EBIT topped out at -$13.7 million in Q3 2024 and bottomed at -$45.7 million in Q3 2022.
  • Average EBIT over 5 years is -$29.2 million, with a median of -$32.3 million recorded in 2021.
  • The sharpest move saw EBIT soared 54.34% in 2024, then crashed 134.67% in 2025.
  • Year by year, EBIT stood at -$44.8 million in 2021, then increased by 17.92% to -$36.7 million in 2022, then increased by 10.78% to -$32.8 million in 2023, then skyrocketed by 46.62% to -$17.5 million in 2024, then decreased by 0.05% to -$17.5 million in 2025.
  • Business Quant data shows EBIT for HCAT at -$17.5 million in Q3 2025, -$37.1 million in Q2 2025, and -$20.2 million in Q1 2025.